Transforming Clinical Trials with Generative AI: Insights from Medable
In this interview, we speak with Tim Smith, co-founder and CTO at Medable, to discuss AI’s role in addressing...
Addressing Clinical Trial Diversity: Challenges, Opportunities, and Critical Capabilities
The 2024 SCOPE Europe conference featured a presentation on clinical trial diversity, highlighting the critical need for diversity and...
Stem Cell Market Growth, Challenges, and Opportunities to 2028
The global induced pluripotent stem cells (iPSCs) market is poised for significant growth, projected to increase from $3.4 billion...
Rlyb212 Dosing in Pregnant Women: Target-Mediated Drug Disposition
Rallybio Corporation published a manuscript detailing a novel model for determining drug dosage in pregnant women, specifically for their...
ImmunoTech Announces Cash Conservation Plan
AIM ImmunoTech Inc. has launched a cash conservation plan to support its clinical trials and drug development, particularly for...
FDA Approves Rapiblyktm for Atrial Fibrillation and Flutter
The FDA has approved Rapiblyk (landiolol), an ultra-short-acting beta-blocker, for the short-term treatment of supraventricular tachycardia (SVT), including atrial...
EU Approves Tevimbra for Esophageal and Gastric Cancer
The European Commission approved BeiGene’s tislelizumab (TEVIMBRA), combined with chemotherapy, for first-line treatment of esophageal squamous cell carcinoma (ESCC)...
Acadia Gets Exclusive Saniona San711 License
Acadia Pharmaceuticals has licensed SAN711, a first-in-class drug, from Saniona for global development and commercialization. The drug is targeted...
Arrowhead Pharmaceuticals Reports Strong 2024 Fiscal Year-End Results
Arrowhead Pharmaceuticals announced its financial results for the 2024 fiscal year, highlighting the submission of its first New Drug...
Claudin 18.2 Targeted Therapy Market Forecast 2024-2029
Claudin 18.2, a protein typically found in tight junctions, has emerged as a promising therapeutic target for various cancers,...